Mira WKN: A3EQWL ISIN: US60458C1045 Kürzel: MIRA Forum: Aktien User: 00000

Corporate Event Alert for MIRA Pharmaceuticals Inc. (MIRA) Positive surprise of 26.67%. Expected EPS of -0.15 and actual EPS of -0.11 Quarter Ended May 31, 2025 Expected EPS -0.15 Actual EPS -0.11 Surprise 26.67%

Die Aktie ist eben mal komplett durch die Decke gegangen. Da haben dann aber scheinbar einige Stopps ausgelöst und wir sind wieder ordentlich gefallen. Mal abwarten was um 15:30 Uhr passiert.

MIRA Pharmaceuticals Announces Board Approval of SKNY Acquisition Reflecting $60+ Million in Combined Enterprise Value Based on Independent Review

😳😳😳😳

https://seekingalpha.com/news/4423957-mira-pharmaceuticals-signs-loi-to-acquire-skny-pharmaceuticals?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news

https://www.finanznachrichten.de/nachrichten-2025-03/64813898-mira-pharmaceuticals-expands-ketamir-2-development-with-topical-treatment-for-localized-neuropathic-and-inflammatory-pain-200.htm

⬆️

📌swing

⬆️

🔣

🌻

@everyone WL for PM AIMD .60-.65 PB w sl under .55 or .75 breakout. Levels .56/.60/.65/.75/.84/.94/1 LGMK .27-.30 PB w sl under .25 or AH highs breakout. Levels .21/.25/.27/.30/.36/.40/.45/.53/.60 MIRA 2.10 PB w sl under 2 or 2.35 breakout Levels 2/2.10/2.25/2.35/2.50/2.60/2.75/3

$MIRA Preclinical Success with Ketamir-2: Drug Candidate: MIRA Pharmaceuticals provided an update on its drug candidate, Ketamir-2, focusing on its principal metabolite, Nor-Ketamir-2. New Findings: The company unveiled promising preclinical data indicating that Nor-Ketamir-2 is a longer-acting, brain-penetrating, and selective compound. It interacts specifically with the NMDA Complex's PCP receptor while avoiding activity on the glutamate NMDA site, which could potentially offer a more targeted therapeutic approach. Enhanced Formulation: A new salt formulation of Ketamir-2, called Ketamir-2 Pamoate, has been developed to improve its pharmacokinetics. This formulation has shown nearly 100% oral bioavailability and improved brain penetration. Regulatory Progress: MIRA Pharmaceuticals is actively working on Investigational New Drug (IND)-enabling studies and scaling up the drug under Good Manufacturing Practice (GMP) standards. The company plans to submit an IND application by the end of 2024, aiming to begin clinical trials shortly after.

🌻

🥃

Immer im Auge behalten….. The company has 6.3 months of cash left based on quarterly cash burn of -$1.05M and estimated current cash of $2.2M.